Loading...

PHGE BIOMX INC Expansion Plans 8-K Filing

BMX

PHG

BIOMX INC

(PHGE)

2025 8-K

Business Strategy Shift

Supply Agreement Signed

Acquisition Completed

Stockholder Meeting

Acquisition Completed

Acquisition Agreement

Delisting Notice

Warrant Amendment

Stockholder Meeting Results

Management Changes

Executive Changes

Control Change Report

Board Appointments

Lease Termination

Funding Agreement

BiomX Insolvency Application

Clinical Trial Update

FDA Clinical Hold Update

Stock Split Announcement

Financial Results Announced

Annual Meeting Results

FDA Clinical Hold

Financial Results

New Product Launches

Investor Meetings

Earnings Releases

Rights Offerings

Positive Trial Results

Financial Results

Compliance Regained

Q3 Financial Results

Investor Update

Stock Split Announcement

Annual Meeting Results

Amendment to Acquisition Fi...

Board Appointment

Earnings Reports

Appointment of Directors

Acquisition Completion

Merger Agreement

Agreement for Stock Offering

Refiling of Financial State...

Positive Trial Results

Financial Results Announcement

Option Repricing and Option...

Appointment of Director

Earnings Reports

Annual Meeting of Stockholders

Results of Operations and F...

Private Placement Offering

Special Meeting of Stockhol...

Financial Results and Annua...

Private Placement

Private Placement

Investor Conferences

External Links:

On December 8, 2025, BiomX Inc. announced the discontinuation of its clinical trial for drug candidate BX004 designed to treat Cystic Fibrosis, citing resource constraints. The company will now focus on developing BX011 for diabetic foot infections and implement significant workforce reductions.

AI Assistant

BIOMX INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.